Table 3 Efficacy outcome measurements for the included studies

Li et al. 2022 [18]

TS + CT

CT

33

33

60.61%

33.33%

12.12 (8.50-13.91)

7.65 (3.88–10.52)

N/A

N/A

27 (81.82)

19 (57.58)

Lu et al. 2021 [19]

TS + CT

CT

223

111

57.4 (50.6–64.0)

36.9 (28.0–46.6)

9.7 (7.7–11.5)

7.6 (5.6–8.0)

Hazard ratio = 0.65 (0.46–0.90), p = 0.004

8.5 (6.80–10.58)

6.0 (4.99–not estimable)

N/A

N/A

Wang et al. 2021 [20]

Arm A: TS + CT (PTX + CBP)

Arm B: TS + CT (nab PTX + CBP)

Arm C: CT (PTX + CBP)

120

119

121

73 (63.6–80.3)

75 (66.0-82.3)

50 (40.4–58.8)

7.6 (6.0-9.8)

7.6 (5.8–11.0)

5.5 (4.2–5.7)

A versus C: Hazard

ratio = 0.52 (0.37–0.74), p < 0.001

B versus C: Hazard

ratio = 0.48 (0.34–0.68), p < 0.001

8.2 (5.0-not estimable)

8.6 (6.3-not estimable)

4.2 (2.8–4.9)

N/A

N/A

Zhou et al. 2022 [21]

TS

CT

535

270

22.6 (19.1–26.4)

7.1 (4.3–10.8)

4.2 (3.9–5.5)

2.6 (2.2–3.8)

Hazard ratio = 0.63 (0.53–0.75), p < 0.0001

13.5 (8.5–19.6)

6.0 (2.1–7.2)

298 (55.70)

114 42.20